What Does a 22% Jump at IDEXX Laboratories (NASDAQ:IDXX) Signal for Revvity (NYSE:RVTY), Tempus AI (NASDAQ:TEM) and Stevanato Group (NYSE:STVN)?

Vinay Lochav

05 November 2026 12:49 AM AEDT

What Does a 22% Jump at IDEXX Laboratories (NASDAQ:IDXX) Signal for Revvity (NYSE:RVTY), Tempus AI (NASDAQ:TEM) and Stevanato Group (NYSE:STVN)?

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key Highlights

IDEXX Laboratories (NASDAQ:IDXX) gained about 22% on November 2, 2026, closing near USD 671.64 after Revenue rose 10% to about USD 1.214 billion and diluted Earnings of USD 4.01 a share beat estimates.
Revvity (NYSE:RVTY) closed up 7.84% on November 3 after revenue of USD 728.9 million and pro forma adjusted earnings guidance of USD 5.40 to USD 5.45 a share for 2026.
Tempus AI (NASDAQ:TEM) rose 8.67% on November 2 after revenue grew 23% to USD 411.5 million and adjusted EBITDA reached USD 25.6 million for the first time.
Stevanato Group (NYSE:STVN) fell about 24% to 26% on November 3 after guiding low single-digit revenue growth for 2027, even though third-quarter revenue rose 8% to EUR 326.1 million.

IDEXX Laboratories (NASDAQ:IDXX): Repeating Revenue and a Raised Guide

IDEXX Laboratories (NASDAQ:IDXX) reported third-quarter results on November 2, 2026. Revenue rose 10% to about USD 1.214 billion, against roughly USD 1.19 billion expected, and diluted earnings of USD 4.01 a share rose 18% against a published consensus of USD 3.71. Operating Margin was 33.1%. Recurring diagnostics revenue in the companion animal group reached USD 967 million, up 11%, led by a 14% rise in consumables for in-clinic analysers. The company placed 5,780 premium instruments, including 1,904 of its inVue Dx analysers. Recurring Revenue is the figure investors prize most, because it repeats each quarter. Earnings guidance for 2026 rose to USD 14.96 to USD 15.16, and the shares closed up about 22% at USD 671.64. The same published analysis notes that same-store clinical visits fell 1.8% and rapid assay volumes declined, with price alone keeping those sales growing. If veterinary visits stay soft, Volume growth could slow, and the full-year margin range of 32.1% to 32.3% was trimmed from 32.3% to 32.5%. Organic revenue growth guidance was lifted to 9.3% to 10.0% from 8.5% to 9.7%. Published coverage also notes a seventh straight quarterly earnings beat, which sets a high bar after a 22% rise.

Revvity (NYSE:RVTY): Lab Demand and Pro Forma Complexity

Revvity (NYSE:RVTY) reported third-quarter 2026 results on November 3, for the quarter ended October 4. Reported revenue was USD 728.9 million against USD 698.9 million, and adjusted earnings from continuing operations were USD 1.38 a share against USD 1.18. Life Sciences revenue was USD 379.6 million, with pro forma organic growth of 9% and an adjusted operating margin of 31.5%. Diagnostics revenue was USD 349.3 million, with pro forma organic growth of 5% and a margin of 29.9%. Guidance for 2026 is pro forma revenue of about USD 2.86 billion and pro forma adjusted earnings of USD 5.40 to USD 5.45, excluding its China IDX business. The release says guidance was raised but does not state the prior range. Shares closed up 7.84%. Revvity sells instruments and reagents to research labs, drug makers and diagnostic labs, so funding for academic research and Drug Development drives demand. Pro forma numbers can hide restructuring effects. Diagnostics fell as reported, from USD 356.1 million, even though it grew 5% organically, and reported revenue grew only about 4.3%, simple arithmetic, against 7% pro forma organic growth.

Tempus AI (NASDAQ:TEM): Data and Diagnostics Together

Tempus AI (NASDAQ:TEM) reported third-quarter results on November 2, 2026. Revenue was USD 411.5 million, up 23%, slightly above a consensus near USD 409 million. Diagnostics revenue was USD 303.5 million, up 20%, led by oncology at USD 172.6 million, up 28%, and hereditary testing at USD 111.3 million. Data and applications revenue was USD 108.1 million, up 33%, with data licensing growing 29%. Adjusted EBITDA of USD 25.6 million was the first positive quarter on that measure. 2026 revenue guidance rose to USD 1.60 billion to USD 1.605 billion, with adjusted EBITDA guidance kept at about USD 65 million. The GAAP net loss was USD 14.9 million, according to published coverage, and cash and marketable securities were USD 854.4 million. The shares closed up 8.67%. These figures come from published coverage of the call and release, which could not be matched to the full filing. A Shareholder vote on November 30 and reliance on a few large pharmaceutical customers are the main watch points. Oncology and hereditary testing make up most of diagnostics revenue, and reimbursement and regulatory decisions for tests are a swing factor, as is integration risk from the pending acquisition.

Stevanato Group (NYSE:STVN): The Odd One Out

Stevanato Group (NYSE:STVN) supplies glass vials, syringes and drug-delivery devices to pharmaceutical companies, so it sits in the same healthcare Supply chain as the others. Its third-quarter report on November 3, 2026 showed revenue of EUR 326.1 million against about EUR 320.9 million expected, up 8%, and adjusted earnings of EUR 0.16 a share, in line. The 2026 revenue range of EUR 1.26 billion to EUR 1.28 billion was kept, but management guided only low single-digit revenue growth for 2027. GLP-1 products made up about 17% to 18% of third-quarter revenue, while demand from other biologic drugs grew more than 30%, according to published coverage. One morning snapshot showed a fall of about 25.9% to USD 14.63 against a USD 19.74 close, on volume near four times the three-month average, while another cited about 24%. Risks include customer concentration in obesity drugs, price pressure on injectable devices and slower biologic launches, and the USD 14.63 level is intraday, not a close. A stock that rallies into results has more room to disappoint, so investors should read the 2027 commentary alongside order data without assuming a rebound or a further decline.

Where Things Stand

A 22% jump at IDEXX says the market is rewarding recurring revenue and a raised guide, while the contrast with Stevanato shows it punishes any hint of slower growth. Revvity and Tempus rose less, partly because Revvity's outlook has no stated prior range and Tempus still reports a GAAP loss. IDEXX Laboratories (NASDAQ:IDXX) has the strongest evidence of repeat demand. Stevanato Group (NYSE:STVN) shows how a good quarter can be overshadowed by a weak outlook. The next catalysts are visit trends and fourth-quarter margins at IDEXX, the Tempus vote on November 30 and Stevanato's order data. Single-day moves can reverse. Nothing here is Investment advice.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.